Literature DB >> 16838179

Regulatory T cells and innate immune regulation in tumor immunity.

Rong-Fu Wang1.   

Abstract

Innate and adaptive immunity play important roles in immunosurveillance and tumor destruction. However, increasing evidence suggests that tumor-infiltrating immune cells may have a dual function: inhibiting or promoting tumor growth and progression. Although regulatory T (Treg) cells induce immune tolerance by suppressing host immune responses against self- or nonself-antigens, thus playing critical roles in preventing autoimmune diseases, they might inhibit antitumor immunity and promote tumor growth. Recent studies demonstrate that elevated proportions of Treg cells are present in various types of cancers and suppress antitumor immunity. Furthermore, tumor-specific Treg cells can inhibit immune responses only when they are exposed to antigens presented by tumor cells. Therefore, Treg cells at tumor sites have detrimental effects on immunotherapy directed to cancer. This review will discuss recent progress in innate immunity, Treg cells, and their regulation through Toll-like receptor (TLR) signaling. It was generally thought that TLR-mediated recognition of specific structures of invading pathogens initiate innate and adaptive immune responses through dendritic cells. New evidence suggests that TLR signaling may directly regulate the suppressive function of Treg cells. Linking TLR signaling to the functional control of Treg cells opens intriguing opportunities to manipulate TLR signaling to control both innate and adaptive immunity against cancer.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16838179     DOI: 10.1007/s00281-006-0022-7

Source DB:  PubMed          Journal:  Springer Semin Immunopathol        ISSN: 0344-4325


  100 in total

1.  Role for IL-10 in suppression mediated by peptide-induced regulatory T cells in vivo.

Authors:  Anette Sundstedt; Emma J O'Neill; Kirsty S Nicolson; David C Wraith
Journal:  J Immunol       Date:  2003-02-01       Impact factor: 5.422

2.  Control of Foxp3+ CD25+CD4+ regulatory cell activation and function by dendritic cells.

Authors:  Zoltán Fehérvári; Shimon Sakaguchi
Journal:  Int Immunol       Date:  2004-11-01       Impact factor: 4.823

3.  Inducing and expanding regulatory T cell populations by foreign antigen.

Authors:  Karsten Kretschmer; Irina Apostolou; Daniel Hawiger; Khashayarsha Khazaie; Michel C Nussenzweig; Harald von Boehmer
Journal:  Nat Immunol       Date:  2005-10-23       Impact factor: 25.606

4.  Toll-like receptor 2 controls expansion and function of regulatory T cells.

Authors:  Roger P M Sutmuller; Martijn H M G M den Brok; Matthijs Kramer; Erik J Bennink; Liza W J Toonen; Bart-Jan Kullberg; Leo A Joosten; Shizuo Akira; Mihai G Netea; Gosse J Adema
Journal:  J Clin Invest       Date:  2006-01-19       Impact factor: 14.808

5.  Toll-like receptor 8-mediated reversal of CD4+ regulatory T cell function.

Authors:  Guangyong Peng; Zhong Guo; Yukiko Kiniwa; Kui Shin Voo; Weiyi Peng; Tihui Fu; Daniel Y Wang; Yanchun Li; Helen Y Wang; Rong-Fu Wang
Journal:  Science       Date:  2005-08-26       Impact factor: 47.728

6.  Foxp3 programs the development and function of CD4+CD25+ regulatory T cells.

Authors:  Jason D Fontenot; Marc A Gavin; Alexander Y Rudensky
Journal:  Nat Immunol       Date:  2003-03-03       Impact factor: 25.606

7.  Induction of FoxP3 and acquisition of T regulatory activity by stimulated human CD4+CD25- T cells.

Authors:  Mindi R Walker; Deborah J Kasprowicz; Vivian H Gersuk; Angele Benard; Megan Van Landeghen; Jane H Buckner; Steven F Ziegler
Journal:  J Clin Invest       Date:  2003-11       Impact factor: 14.808

Review 8.  Regulatory T cells and Toll-like receptors in tumor immunity.

Authors:  Rong-Fu Wang; Guangyong Peng; Helen Y Wang
Journal:  Semin Immunol       Date:  2006-02-15       Impact factor: 11.130

9.  Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer.

Authors:  Lin Zhang; Jose R Conejo-Garcia; Dionyssios Katsaros; Phyllis A Gimotty; Marco Massobrio; Giorgia Regnani; Antonis Makrigiannakis; Heidi Gray; Katia Schlienger; Michael N Liebman; Stephen C Rubin; George Coukos
Journal:  N Engl J Med       Date:  2003-01-16       Impact factor: 91.245

10.  Conversion of peripheral CD4+CD25- naive T cells to CD4+CD25+ regulatory T cells by TGF-beta induction of transcription factor Foxp3.

Authors:  WanJun Chen; Wenwen Jin; Neil Hardegen; Ke-Jian Lei; Li Li; Nancy Marinos; George McGrady; Sharon M Wahl
Journal:  J Exp Med       Date:  2003-12-15       Impact factor: 14.307

View more
  22 in total

1.  Histone deacetylase 11: A novel epigenetic regulator of myeloid derived suppressor cell expansion and function.

Authors:  Eva Sahakian; John J Powers; Jie Chen; Susan L Deng; Fengdong Cheng; Allison Distler; David M Woods; Jennifer Rock-Klotz; Andressa L Sodre; Je-In Youn; Karrune V Woan; Alejandro Villagra; Dmitry Gabrilovich; Eduardo M Sotomayor; Javier Pinilla-Ibarz
Journal:  Mol Immunol       Date:  2014-08-23       Impact factor: 4.407

2.  Trial watch: Naked and vectored DNA-based anticancer vaccines.

Authors:  Norma Bloy; Aitziber Buqué; Fernando Aranda; Francesca Castoldi; Alexander Eggermont; Isabelle Cremer; Catherine Sautès-Fridman; Jitka Fucikova; Jérôme Galon; Radek Spisek; Eric Tartour; Laurence Zitvogel; Guido Kroemer; Lorenzo Galluzzi
Journal:  Oncoimmunology       Date:  2015-04-02       Impact factor: 8.110

3.  Resiquimod as an immunologic adjuvant for NY-ESO-1 protein vaccination in patients with high-risk melanoma.

Authors:  Rachel Lubong Sabado; Anna Pavlick; Sacha Gnjatic; Crystal M Cruz; Isabelita Vengco; Farah Hasan; Meredith Spadaccia; Farbod Darvishian; Luis Chiriboga; Rose Marie Holman; Juliet Escalon; Caroline Muren; Crystal Escano; Ethel Yepes; Dunbar Sharpe; John P Vasilakos; Linda Rolnitzsky; Judith Goldberg; John Mandeli; Sylvia Adams; Achim Jungbluth; Linda Pan; Ralph Venhaus; Patrick A Ott; Nina Bhardwaj
Journal:  Cancer Immunol Res       Date:  2015-01-29       Impact factor: 11.151

4.  Hepatocellular carcinoma and macrophage interaction induced tumor immunosuppression via Treg requires TLR4 signaling.

Authors:  Jing Yang; Jin-Xiang Zhang; Hui Wang; Guo-Liang Wang; Qing-Gang Hu; Qi-Chang Zheng
Journal:  World J Gastroenterol       Date:  2012-06-21       Impact factor: 5.742

5.  A role for T-bet-mediated tumour immune surveillance in anti-IL-17A treatment of lung cancer.

Authors:  S Reppert; I Boross; M Koslowski; Ö Türeci; S Koch; H A Lehr; S Finotto
Journal:  Nat Commun       Date:  2011-12-20       Impact factor: 14.919

6.  Effects of iodine-131 radiotherapy on Th17/Tc17 and Treg/Th17 cells of patients with differentiated thyroid carcinoma.

Authors:  Lixia Zhang; Jinyan Chen; Caiyun Xu; Lili Qi; Yan Ren
Journal:  Exp Ther Med       Date:  2017-12-21       Impact factor: 2.447

7.  Circulating T regulatory cells migration and phenotype in glioblastoma patients: an in vitro study.

Authors:  Chiara Vasco; Alessandra Canazza; Ambra Rizzo; Adele Mossa; Elena Corsini; Antonio Silvani; Laura Fariselli; Andrea Salmaggi; Emilio Ciusani
Journal:  J Neurooncol       Date:  2013-09-05       Impact factor: 4.130

8.  The role of regulatory T cells in cancer.

Authors:  Tai-You Ha
Journal:  Immune Netw       Date:  2009-12-31       Impact factor: 6.303

9.  IFN-alpha enhances peptide vaccine-induced CD8+ T cell numbers, effector function, and antitumor activity.

Authors:  Andrew G Sikora; Nina Jaffarzad; Yared Hailemichael; Alexander Gelbard; Spencer W Stonier; Kimberly S Schluns; Loredana Frasca; Yanyan Lou; Chengwen Liu; Helen A Andersson; Patrick Hwu; Willem W Overwijk
Journal:  J Immunol       Date:  2009-06-15       Impact factor: 5.422

10.  T regulatory cell markers in oral squamous cell carcinoma: Relationship with survival and tumor aggressiveness.

Authors:  Geane Moreira; Lívia Bonfim Fulgêncio; Elismauro Francisco DE Mendonça; Cláudio Rodrigues Leles; Aline Carvalho Batista; Tarcília Aparecida DA Silva
Journal:  Oncol Lett       Date:  2010-01-01       Impact factor: 2.967

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.